Online inquiry

IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12896MR)

This product GTTS-WQ12896MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12896MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11372MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ3296MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ8041MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ9806MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ14167MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ7497MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ11591MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ3663MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW